Welcome to our dedicated page for Aridis Pharmaceuticals news (Ticker: ARDS), a resource for investors and traders seeking the latest updates and insights on Aridis Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aridis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aridis Pharmaceuticals's position in the market.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced participation in the Cantor Fitzgerald Virtual Symposium titled "Winning Ways to Treat Infections and COVID-19," scheduled for June 30, 2020, at 11:00 AM ET. CEO Vu Truong will represent the company, which focuses on developing novel anti-infective therapies for severe bacterial infections. Aridis utilizes its proprietary technology platforms to create monoclonal antibodies (mAbs) targeting life-threatening infections and is advancing several clinical programs.
Aridis Pharmaceuticals (Nasdaq: ARDS) announced positive outcomes from the Phase 1 part of its Phase 1/2a clinical trial for AR-501, an inhaled gallium citrate formulation targeting chronic lung infections in cystic fibrosis (CF) patients. Funded by the Cystic Fibrosis Foundation, the trial showed that AR-501 was well tolerated, with no serious adverse events reported. The next phase will evaluate adults with CF, with results anticipated in 2H 2021. AR-501 has received multiple FDA designations, highlighting its potential therapeutic benefits in the treatment of stubborn lung infections.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced its participation in a Cantor Fitzgerald Virtual Fireside Chat on June 25, 2020, at 11:00 AM ET. The discussion will focus on the company's APEX™ technology platform, which aims to rapidly discover treatments for emerging pathogens, including COVID-19. Aridis will also update on its clinical programs, particularly AR-301, currently in Phase 3 trials for ventilator-associated pneumonia, and AR-501, targeting chronic pulmonary infections in cystic fibrosis patients. The chat will feature insights from CEO Vu Truong and CMO Hasan Jafri.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) has appointed Dr. Hasan Jafri as Chief Medical Officer, replacing interim CMO Dr. Paul Mendelman, who will transition to a senior medical advisor role. Dr. Jafri brings over 25 years of experience in infectious diseases, having previously served at AstraZeneca as Senior Medical Director. His expertise includes developing monoclonal antibodies targeting serious bacterial infections. Aridis focuses on discovering novel anti-infective therapies, leveraging its APEX and MabIgX technology platforms to address critical infections and antibiotic resistance.